2021 ISAKOS Biennial Congress ePoster
PRP in ACL Reconstruction Does Not Improve Clinical and Functional Outcomes: Results from a Prospective Randomized Clinical Study at 12 Years Follow-Up
David H. Figueroa, MD, Santiago, RM CHILE
Rodrigo Guiloff, MD, Prof, Santiago, Vitacura CHILE
Rafael Calvo, MD, Santiago CHILE
Luis A. O'Connell, MD, Santiago, Colina CHILE
Francisco Figueroa, MD, Santiago, RM CHILE
Alex Vaisman, MD, Prof., Santiago, RM CHILE
Facultad de Medicina ClĂnica Alemana - Universidad del Desarrollo, Santiago, Metropolitana, CHILE
FDA Status Cleared
Summary
Prospective, randomized clinical study in 50 patients who underwent an anatomic tunnel ACL-R technique with autologous hamstring graft. In this clinical series, PRP in ACL-R did not improve clinical or functional outcomes at 12 years of follow-up.
ePosters will be available shortly before Congress
Abstract
Purpose
This study aimed to compare the long-term effect of autologous platelet-rich-plasma concentrate (PRP) in anterior cruciate ligament reconstruction (ACL-R). The hypothesize was that PRP did not affect clinical and functional outcomes.
Methods
Prospective, randomized clinical study in 50 patients who underwent an anatomic tunnel ACL-R technique with autologous hamstring graft. Patients were randomly assigned into two study groups: Intervention Group (30 patients with PRP enhancement during the procedure) and Control Group (20 patients). Multiligamentary knee injuries and revision surgeries were excluded. At a minimum follow-up of 10 years, groups were compared for knee reintervention of any cause, range of motion (ROM), and functional outcomes (Lysholm, Tegner, and IKDC). Statistical analysis included Student's t and U Mann-Whitney tests. Significance was set at p<0.05.
PRP was obtained from a venous blood sample of each patient during the ACL-R procedure. Following the reconstruction and intra-articular fluid removal, 10 ml of PRP were applied into both bone tunnels (3ml each) and the intra-articular graft portion (4ml).
Results
Groups [Intervention/Control] did not differ regarding mean age [29 years (14-52)/25 years (15-53); p=0.14], male sex [68%/81%; p=0.17. Mean follow-up: 12 (11-13) years [Intervention group 12 years (11-12)/Control group 12 years (11-14)].
No statistical difference were found between groups for surgical reinterventions (p=0.37), ROM (0.25) and functional outcomes (Lysholm p=0.68; IKDC p=0.55; and Tegner p=0.90)
Conclusions
In this clinical series, PRP in ACL-R did not improve clinical or functional outcomes at 12 years of follow-up.